Projet NATPRIME (Horizon Europe, appel à projets 2023)
Action : Doctoral Networks
Panel : Chemistry
Statut du projet : SIGNED

Delivery of Nucleic Acid Therapeutics to desired organs has become the current challenge of biotechnological applications. Advancements on the chemical synthesis or targeting ligands, formulation of complex lipid systems, and their bioassays are essential to establish new gene therapies. Therefore, the main aim of NATPRIME DN is to establish a multidisciplinary training network on the emerging topic of nanoparticle-based adjuvants to deliver nucleic acid therapeutics (NAT). In the last decade, great efforts have been spent on the development of synthetic strategies for the creation of RNA based therapies/vaccines, and these efforts have been acknowledged by the Nobel committee in 2023. The next important step is targeted delivery, which is to carry NATs to the desired tissue. For this purpose, various nanoassemblies, i.e lipid nanoparticles, polyplexes, liposomes, that are modified with targeting ligands will be utilised to encapsulate NATS. Antibodies, peptides, glycans, and glycopolymers open up greater possibilities in the precise targeting of nanoparticles to desired organs/tissues/cells. The combined molecular toolbox of targeting ligands, charged lipids, helper lipids and PEG-replacement lipids need a high-throughput formulation-screening to ensure increased uptake of such particles in the desired organs. 15 interdisciplinary researchers will be trained on the design, synthesis, and characterisation of such complex targeting ligands, their formulation in nanoparticles, and their utilisation in the nucleic acid based treatments. Last but not least, biophysical understanding of molecular interactions of formulation components will bridge the gap between fundamental and applied research while broadening the horizon of ESRs from an academic lab to good manufacturing practice (GMP) synthesis facilities that can positively impact the well-being of future generations.

Mots clés : lipid nanoparticles, glycopolymers, nucleic acid delivery

Participants :
- Université de Copenhague (Danemark) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université de Strathclyde (Royaume-Uni) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Croda denmark a/s (Danemark) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- AstraZeneca (Sweden) (Suède) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 293709.6 €
- Université de Fribourg-en-Brisgau (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 521078.4 €
- Statens Serum Institut (Danemark) — Partner, beneficiary, Recherche, subvention : 301788.0 €
- Université du Bosphore (Turquie) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université de technologie d'Eindhoven (Pays-Bas) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 548740.8 €
- Université de Bordeaux (France) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 565387.2 €
- Université de Warwick (Royaume-Uni) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université Louis-et-Maximilien de Munich (Allemagne) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Société Max-Planck pour le développement des sciences (Allemagne) — Partner, beneficiary, Recherche, subvention : 521078.4 €
- Université de Gand (Belgique) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 525240.0 €
- Polymun (Austria) (Autriche) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Imperial College London (Royaume-Uni) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Príncipe Felipe Research Center (Espagne) — Partner, beneficiary, Recherche, subvention : 503942.4 €
- Rs arastirma egitim danismanlik ilac sanayi ticaret anonim sirketi (Turquie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 219168.0 €